PDC and acute kidney injury: Since HIF is necessary for erythropoiesis induction, PHI roxadustat and GSK1278863 also has been proposed for anemia treatment in CKD, demonstrating the increase in erythropoietin and hematocrit levels in animal models [103,104] and even in patients [105]; hence in CKD and AKI, there is an increase in PHD activity, and their inhibition ameliorates damage associated with kidney dysfunction.